Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study | Zendy

Prithviraj Bose | Zendy; David McCue | Zendy; Sebastian Wurster | Zendy; Nathan P. Wiederhold | Zendy; Marina Konopleva | Zendy; Tapan M. Kadia | Zendy; Gautam Borthakur | Zendy; Farhad Ravandi | Zendy; Lucia Masárová | Zendy; Koichi Takahashi | Zendy; Zeev Estrov | Zendy; Musa Yılmaz | Zendy; Naval Daver | Zendy; Naveen Pemmaraju | Zendy; Kiran Naqvi | Zendy; Caitlin R. Rausch | Zendy; Kayleigh R. Marx | Zendy; Wei Qiao | Zendy; Xuelin Huang | Zendy; Carol Bivins | Zendy; Sherry Pierce | Zendy; Hagop M. Kantarjian | Zendy; Dimitrios P. Kontoyiannis | Zendy

Open Access

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

Author(s) -

Prithviraj Bose,

David McCue,

Sebastian Wurster,

Nathan P. Wiederhold,

Marina Konopleva,

Tapan M. Kadia,

Gautam Borthakur,

Farhad Ravandi,

Lucia Masárová,

Koichi Takahashi,

Zeev Estrov,

Musa Yılmaz,

Naval Daver,

Naveen Pemmaraju,

Kiran Naqvi,

Caitlin R. Rausch,

Kayleigh R. Marx,

Wei Qiao,

Xuelin Huang,

Carol Bivins,

Sherry Pierce,

Hagop M. Kantarjian,

Dimitrios P. Kontoyiannis

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa358

Subject(s) - medicine , tolerability , neutropenia , clinical endpoint , myelodysplastic syndromes , myeloid leukemia , regimen , dosing , febrile neutropenia , chemotherapy , gastroenterology , surgery , adverse effect , clinical trial , bone marrow

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research